Psychopathological Symptoms in Patients with Primary Hyperaldosteronism – Possible Pathways

 

 Buy Article Permissions and Reprints

Abstract

A close comorbidity between endocrine diseases and psychopathological symptoms has been described in the literature. Until now only a few studies have reported about an increased anxiety and depressive symptoms in patients with primary hyperaldosteronism (PHA). The exact pathways of psychiatric comorbidities have not been totally clarified yet, although the renin-angiotensin-aldosterone-system has gained more attention in research on anxiety and depression. There are several structures and factors, which could mediate anxiety or a depressive symptomatology. Additionally a possible influence of the standardised treatment with a mineralocorticoidreceptor (MR) antagonist or adrenalectomy should be investigated as they have been shown to affect mood. Psychiatric comorbidities are not only an additional burden in these patients, but as depression and anxiety are additional risk factors in patients with cardiovascular diseases. Possible pathomechanisms in the relation between PHA and psychiatric symptoms should be more closely investigated. For the clinical practice a regular screening for psychiatric comorbidities and an adequate treatment are required.

• References

• 1 Sonino N, Fallo F, Fava GA. Psychosomatic aspects of Cushing's syndrome. Rev Endocr Metab Disord 2010; 11: 95-104
  CrossrefPubMedGoogle Scholar
• 2 Tiemensma J, Biermasz NR, van der Mast RC, Wassenaar MJ, Middelkoop HA, Pereira AM, Romijn JA. Increased Psychopathology and Maladaptive Personality Traits, But Normal Cognitive Functioning, In Patients after Long-Term Cure of Acromegaly. J Clin Endocrinol Metab 2010; 95: E392-E402
  CrossrefPubMedGoogle Scholar
• 3 Barnett PS, Palazidou E, Miell JP, Coskeran PB, Butler J, Dawson JM, Maccabe J, McGregor AM. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502. Q J Med 1991; 81: 891-906
  PubMedGoogle Scholar
• 4 Bunevicius R, Prange Jr AJ. Thyroid disease and mental disorders: cause and effect or only comorbidity?. Curr Opin Psychiatry 2010; 23: 363-368
  CrossrefPubMedGoogle Scholar
• 5 Avery TL. Primary hyperaldosteronism and depression. N Z Med J 1984; 97: 537
  PubMedGoogle Scholar
• 6 Khurshid KA, Weaver ME. Conn’s syndrome presenting as depression. Am J Psychiatry 2005; 162: 1226
  PubMedGoogle Scholar
• 7 Malinow KC, Lion JR. Hyperaldosteronism (Conn’s disease) presenting as depression. J Clin Psychiatry 1979; 40: 358-359
  PubMedGoogle Scholar
• 8 Tritos NA. Diagnosis of primary aldosteronism in a patient with an incidentally found adrenal mass. Nat Clin Pract Endocrinol Metab 2007; 3: 547-551
  CrossrefPubMedGoogle Scholar
• 9 Sonino N, Fallo F, Fava GA. Psychological aspects of primary aldosteronism. Psychother Psychosom 2006; 75: 327-330
  CrossrefPubMedGoogle Scholar
• 10 Sonino N, Tomba E, Genesia ML, Bertello C, Mulatero P, Veglio F, Fava GA, Fallo F. Psychological Assessment of Primary Aldosteronism: A Controlled Study. J Clin Endocrinol Metab 2011; 96: E878-E883
  CrossrefPubMedGoogle Scholar
• 11 Apostolopoulou K, Künzel H, Gerum S, Merkle K, Schulz S, Fischer E, Pallauf A, Brand V, Bidlingmaier M, Endres S, Beuschlein F, Reincke M. Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross sectional study. World J Biol Psychiatry: accepted.
  PubMedGoogle Scholar
• 12 Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2010; 95: 1360-1364
  Google Scholar
• 13 Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 2011; 96: 2904-2911
  Google Scholar
• 14 Lippi G, Montagnana M, Favaloro EJ, Franchini M. Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost 2009; 35: 325-336
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003; 290: 215-221
  CrossrefPubMedGoogle Scholar
• 16 Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501
  CrossrefPubMedGoogle Scholar
• 17 Strohle A, Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 2003; 36: S207-S214
  PubMedGoogle Scholar
• 18 Kem DC, Weinberger MH, Gomez-Sanchez C, Kramer NJ, Lerman R, Furuyama S, Nugent CA. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism. J Clin Invest 1973; 52: 2272-2277
  CrossrefPubMedGoogle Scholar
• 19 de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005; 6: 463-475
  CrossrefPubMedGoogle Scholar
• 20 De Kloet ER, Derijk R. Signaling pathways in brain involved in predisposition and pathogenesis of stress-related disease: genetic and kinetic factors affecting the MR/GR balance. Ann N Y Acad Sci 2004; 1032: 14-34
  CrossrefPubMedGoogle Scholar
• 21 Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391-404
  CrossrefPubMedGoogle Scholar
• 22 Yau JL, Hibberd C, Noble J, Seckl JR. The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. Brain Res Mol Brain Res 2002; 106: 117-123
  CrossrefPubMedGoogle Scholar
• 23 Seckl JR, Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992; 55: 621-626
  CrossrefPubMedGoogle Scholar
• 24 Yau JL, Noble J, Hibberd C, Seckl JR. Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci Lett 2001; 306: 161-164
  CrossrefPubMedGoogle Scholar
• 25 Hlavacova N, Jezova D. Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav 2008; 54: 90-97
  CrossrefPubMedGoogle Scholar
• 26 Hlavacova N, Bakos J, Jezova D. Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release. J Psychopharmacol 2010; 24: 779-786
  CrossrefPubMedGoogle Scholar
• 27 Zhou M, Bakker EH, Velzing EH, Berger S, Oitzl M, Joels M, Krugers HJ. Both mineralocorticoid and glucocorticoid receptors regulate emotional memory in mice. Neurobiol Learn Mem 2010; 94: 530-537
  CrossrefPubMedGoogle Scholar
• 28 Ferguson D, Sapolsky R. Overexpression of mineralocorticoid and transdominant glucocorticoid receptor blocks the impairing effects of glucocorticoids on memory. Hippocampus 2008; 18: 1103-1111
  CrossrefPubMedGoogle Scholar
• 29 Schulz K, Korz V. Emotional and cognitive information processing: relations to behavioral performance and hippocampal long-term potentiation in vivo during a spatial water maze training in rats. Learn Mem 2010; 17: 552-560
  CrossrefPubMedGoogle Scholar
• 30 Lopez JF, Chalmers DT, Little KY, Watson SJ. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998; 43: 547-573
  CrossrefPubMedGoogle Scholar
• 31 Xing GQ, Russell S, Webster MJ, Post RM. Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 2004; 7: 143-153
  CrossrefPubMedGoogle Scholar
• 32 Wang SS, Kamphuis W, Huitinga I, Zhou JN, Swaab DF. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry 2008; 13: 786-799
  CrossrefPubMedGoogle Scholar
• 33 Klok MD, Alt SR, Irurzun Lafitte AJ, Turner JD, Lakke EA, Huitinga I, Muller CP, Zitman FG, Ronald de Kloet E, Derijk RH. Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder. J Psychiatr Res 2011; 45: 871-878
  CrossrefPubMedGoogle Scholar
• 34 Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure?. Hypertension 2008; 51: 727-733
  CrossrefPubMedGoogle Scholar
• 35 Hlavacova N, Wes PD, Ondrejcakova M, Flynn ME, Poundstone PK, Babic S, Murck H, Jezova D. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol 2011; 1-19
  PubMedGoogle Scholar
• 36 Johnson AK, Grippo AJ. Sadness and broken hearts: neurohumoral mechanisms and co-morbidity of ischemic heart disease and psychological depression. J Physiol Pharmacol 2006; 57 (Suppl. 11) 5-29
  PubMedGoogle Scholar
• 37 Holsboer F, Gerken A, Stalla GK, Muller OA. Blunted aldosterone and ACTH release after human CRH administration in depressed patients. Am J Psychiatry 1987; 144: 229-231
  PubMedGoogle Scholar
• 38 Murck H, Held K, Ziegenbein M, Kunzel H, Koch K, Steiger A. The renin-angiotensin-aldosterone system in patients with depression compared to controls – a sleep endocrine study. BMC Psychiatry 2003; 3: 15
  CrossrefPubMedGoogle Scholar
• 39 Emanuele E, Geroldi D, Minoretti P, Coen E, Politi P. Increased plasma aldosterone in patients with clinical depression. Arch Med Res 2005; 36: 544-548
  CrossrefPubMedGoogle Scholar
• 40 Hallberg L, Westrin A, Isaksson A, Janelid S, Träskman-Bendz L, Brundin L. Decreased aldosterone in the plasma of suicide attempters with major depressive disorder. Psychiatry Res 2011; 187: 135-139
  CrossrefPubMedGoogle Scholar
• 41 Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001; 62: 77-91
  CrossrefPubMedGoogle Scholar
• 42 Venning EH, Dyrenfurth I, Beck JC. Effect of anxiety upon aldosterone excretion in man. J Clin Endocrinol Metab 1957; 17: 1005-1008
  CrossrefPubMedGoogle Scholar
• 43 Hullin RP, Jerram TC, Lee MR, Levell MJ, Tyrer SP. Renin and aldosterone relationships in manic depressive psychosis. Br J Psychiatry 1977; 131: 575-581
  CrossrefPubMedGoogle Scholar
• 44 Altamura AC, Gomeni R, Sacchetti E, Smeraldi E. Plasma and intracellular kinetics of lithium after oral administration of various lithium salts. Eur J Clin Pharmacol 1977; 12: 59-63
  CrossrefPubMedGoogle Scholar
• 45 Altamura AC, Morganti A. Plasma renin activity in depressed patients treated with increasing doses of lithium carbonate. Psychopharmacologia 1975; 45: 171-175
  CrossrefPubMedGoogle Scholar
• 46 Murck H, Uhr M, Ziegenbein M, Kunzel H, Held K, Antonijevic IA, Schussler P, Steiger A. Renin-angiotensin-aldosterone system, HPA-axis and sleep-EEG changes in unmedicated patients with depression after total sleep deprivation. Pharmacopsychiatry 2006; 39: 23-29
  Article in Thieme ConnectPubMedGoogle Scholar
• 47 Saavedra JM, Ando H, Armando I, Baiardi G, Bregonzio C, Juorio A, Macova M. Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept 2005; 128: 227-238
  CrossrefPubMedGoogle Scholar
• 48 Armando I, Volpi S, Aguilera G, Saavedra JM. Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res 2007; 1142: 92-99
  CrossrefPubMedGoogle Scholar
• 49 Saavedra JM, Armando I, Bregonzio C, Juorio A, Macova M, Pavel J, Sanchez-Lemus E. A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology 2006; 31: 1123-1134
  PubMedGoogle Scholar
• 50 Gard PR, Mandy A, Sutcliffe MA. Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol Psychiatry 1999; 45: 1030-1034
  CrossrefPubMedGoogle Scholar
• 51 Muldoon MF, Waldstein SR, Ryan CM, Jennings JR, Polefrone JM, Shapiro AP, Manuck SB. Effects of six anti-hypertensive medications on cognitive performance. J Hypertens 2002; 20: 1643-1652
  CrossrefPubMedGoogle Scholar
• 52 Hishimoto A, Shirakawa O, Nishiguchi N, Hashimoto T, Yanagi M, Nushida H, Ueno Y, Maeda K. Association between a functional polymorphism in the renin-angiotensin system and completed suicide. J Neural Transm 2006; 113: 1915-1920
  CrossrefPubMedGoogle Scholar
• 53 Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, Lucae S, Zwanzger P, Haberger C, Zill P, Ising M, Deiml T, Uhr M, Illig T, Wichmann HE, Modell S, Nothdurfter C, Holsboer F, Muller-Myhsok B, Moller HJ, Rupprecht R, Bondy B. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 2006; 11: 1003-1015
  CrossrefPubMedGoogle Scholar
• 54 Saab YB, Gard PR, Yeoman MS, Mfarrej B, El-Moalem H, Ingram MJ. Renin-angiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1113-1118
  CrossrefPubMedGoogle Scholar
• 55 Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry 1997; 54: 915-922
  CrossrefPubMedGoogle Scholar
• 56 Sneed JR, Culang-Reinlieb ME. The vascular depression hypothesis: an update. Am J Geriatr Psychiatry 2011; 19: 99-103
  CrossrefPubMedGoogle Scholar
• 57 Hwang JP, Lee TW, Tsai SJ, Chen TJ, Yang CH, Lirng JF, Tsai CF. Cortical and subcortical abnormalities in late-onset depression with history of suicide attempts investigated with MRI and voxel-based morphometry. J Geriatr Psychiatry Neurol 2010; 23: 171-184
  CrossrefPubMedGoogle Scholar
• 58 Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J, Endres S. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm Metab Res 2010; 42: 435-439
  Google Scholar
• 59 Quinkler M, Born-Frontsberg E, Fourkiotis VG. Comorbidities in primary aldosteronism. Horm Metab Res 2010; 42: 429-434
  Google Scholar
• 60 Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010; 6: 363-368
  PubMedGoogle Scholar
• 61 Douma BR, Korte SM, Buwalda B, la Fleur SE, Bohus B, Luiten PG. Repeated blockade of mineralocorticoid receptors, but not of glucocorticoid receptors impairs food rewarded spatial learning. Psychoneuroendocrinology 1998; 23: 33-44
  CrossrefPubMedGoogle Scholar
• 62 Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K, Kellner M. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology 2007; 32: 232-238
  CrossrefPubMedGoogle Scholar
• 63 Braszko JJ. AT(2) but not AT(1) receptor antagonism abolishes angiotensin II increase of the acquisition of conditioned avoidance responses in rats. Behav Brain Res 2002; 131: 79-86
  CrossrefPubMedGoogle Scholar
• 64 Arregui A, Perry EK, Rossor M, Tomlinson BE. Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. J Neurochem 1982; 38: 1490-1492
  CrossrefPubMedGoogle Scholar
• 65 Elkins JS, Douglas VC, Johnston SC. Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology 2004; 62: 363-368
  CrossrefPubMedGoogle Scholar
• 66 Kolsch H, Jessen F, Freymann N, Kreis M, Hentschel F, Maier W, Heun R. ACE I/D polymorphism is a risk factor of Alzheimer’s disease but not of vascular dementia. Neurosci Lett 2005; 377: 37-39
  CrossrefPubMedGoogle Scholar
• 67 Born J, DeKloet ER, Wenz H, Kern W, Fehm HL. Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am J Physiol 1991; 260: E183-E188
  PubMedGoogle Scholar
• 68 Born J, Steinbach D, Dodt C, Fehm HL. Blocking of central nervous mineralocorticoid receptors counteracts inhibition of pituitary-adrenal activity in human sleep. J Clin Endocrinol Metab 1997; 82: 1106-1110
  CrossrefPubMedGoogle Scholar
• 69 Steiger A, Rupprecht R, Spengler D, Guldner J, Hemmeter U, Rothe B, Damm K, Holsboer F. Functional properties of deoxycorticosterone and spironolactone: molecular characterization and effects on sleep-endocrine activity. J Psychiatr Res 1993; 27: 275-284
  CrossrefPubMedGoogle Scholar
• 70 Di Murro A, Petramala L, Cotesta D, Zinnamosca L, Crescenzi E, Marinelli C, Saponara M, Letizia C. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2010; 11: 165-172
  CrossrefPubMedGoogle Scholar
• 71 Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010; 24: 532-537
  CrossrefPubMedGoogle Scholar
• 72 Brandenberger G, Charifi C, Muzet A, Saini J, Simon C, Follenius M. Renin as a biological marker of the NREM-REM sleep cycle: effect of REM sleep suppression. J Sleep Res 1994; 3: 30-35
  CrossrefPubMedGoogle Scholar
• 73 Zhang ZH, Francis J, Weiss RM, Felder RB. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 2002; 283: H423-H433
  PubMedGoogle Scholar
• 74 Hlavacova N, Jezova D. Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. Endocr Regul 2008; 42: 147-153
  PubMedGoogle Scholar
• 75 Hendler NH. Spironolactone prophylaxis in manic-depressive disease. J Nerv Ment Dis 1978; 166: 517-520
  CrossrefPubMedGoogle Scholar
• 76 Juruena MF, Gama CS, Berk M, Belmonte-de-Abreu PS. Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. J Psychopharmacol 2009; 23: 985-987
  CrossrefPubMedGoogle Scholar
• 77 Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999; 33: 181-214
  CrossrefPubMedGoogle Scholar
• 78 Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, Kellner M. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res 2010; 44: 339-346
  CrossrefPubMedGoogle Scholar
• 79 Holmes MC, Yau JL, French KL, Seckl JR. The effect of adrenalectomy on 5-hydroxytryptamine and corticosteroid receptor subtype messenger RNA expression in rat hippocampus. Neuroscience 1995; 64: 327-337
  CrossrefPubMedGoogle Scholar
• 80 Briones-Aranda A, Castillo-Salazar M, Picazo O. Adrenalectomy modifies the hippocampal 5-HT(1A) receptors and the anxiolytic-like effect of 8-OH-DPAT in rats. Pharmacol Biochem Behav 2009; 92: 182-189
  CrossrefPubMedGoogle Scholar
• 81 Coe SG, Tan WW, Fox TP. Cushing’s syndrome due to ectopic adrenocorticotropic hormone production secondary to hepatic carcinoid: diagnosis, treatment, and improved quality of life. J Gen Intern Med 2008; 23: 875-878
  CrossrefPubMedGoogle Scholar
• 82 Mishra AK, Agarwal A, Gupta S, Agarwal G, Verma AK, Mishra SK. Outcome of adrenalectomy for Cushing’s syndrome: experience from a tertiary care center. World J Surg 2007; 31: 1425-1432
  CrossrefPubMedGoogle Scholar
• 83 Ding XF, Li HZ, Yan WG, Gao Y, Li XQ. Role of adrenalectomy in recurrent Cushing’s disease. Chin Med J (Engl) 2010; 123: 1658-1662
  PubMedGoogle Scholar
• 84 Cohen SI. Cushing’s syndrome: a psychiatric study of 29 patients. Br J Psychiatry 1980; 136: 120-124
  CrossrefPubMedGoogle Scholar
• 85 Voigt KH, Bossert S, Bretschneider S, Bliestle A, Fehm HL. Disturbed cortisol secretion in man: contrasting Cushing’s disease and endogenous depression. Psychiatry Res 1985; 15: 341-350
  CrossrefPubMedGoogle Scholar
• 86 Watkins LL, Blumenthal JA, Davidson JR, Babyak MA, McCants Jr CB, Sketch Jr MH. Phobic anxiety, depression, and risk of ventricular arrhythmias in patients with coronary heart disease. Psychosom Med 2006; 68: 651-656
  CrossrefPubMedGoogle Scholar